Novartis Investigative Site

Willow Grove, Pennsylvania 19090

0 studies enrolling now · 4 studies all time

What they study most

Advancing Multiple Sclerosis, Multiple Sclerosis, Non-Hodgkin's Lymphoma, Relapsing Multiple Scelrosis, Relapsing Multiple Sclerosis

Studies at this site

• Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients — Completed
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies — Completed
• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. — Completed
• Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy — Stopped early